Amylyx Pharmaceuticals, Inc.
http://amylyx.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Amylyx Pharmaceuticals, Inc.
BrainStorm Eyes New Phase III Trial For NurOwn In Mild ALS Following BLA Withdrawal
Highly negative FDA advisory committee review and subsequent discussions with the agency made clear the only path forward was a new study, company executives said. Troubled application shows the limits of FDA’s willingness to exercise regulatory flexibility.
Bad News For Amylyx As EMA Upholds Rejection Of ALS Drug Albrioza
The European Medicines Agency stood by its initial decision to recommend against EU approval of Amylyx’s ALS drug Albrioza after a re-examination, but the company remains hopeful that further trial evidence could support a future EU authorization.
Santhera’s Vamorolone For DMD Among Orphan Drugs Up For EU Marketing Decision
The European Medicines Agency is this week due to decide whether to recommend pan-EU marketing authorization for a number of new products.
Regulatory Flexibility: BrainStorm’s Problematic NurOwn BLA May Be A Bridge Too Far For US FDA
Litany of deficiencies, including product quality shortcomings and a failed Phase III clinical efficacy study, may make it impossible for the agency to exercise the type of flexibility it has with the approval of other treatments for ALS and neurodegenerative diseases.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice